# A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Study · id `cardio:ct-nct01847092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01847092](<https://clinicaltrials.gov/study/NCT01847092>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01847092

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

## Technical summary

Registry record NCT01847092. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2020-05-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 154 participants (enrolled count; ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Primary completion: 2015-03 (actual) (ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Results first posted: 2020-05-27 (ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01847092, source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01847092-2020-05-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
- Condition: Chronic Kidney Disease
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): AZD1722
- Intervention (Drug): Placebo
- Lead sponsor: Ardelyx
- Lead sponsor class: INDUSTRY
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Ardelyx (`cardio:org-ardelyx`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: d0de40f6d01d07c8fc23b25c0c9937f510287a862a9954f701b18bdd3e358c37
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
